International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2024: 7.101

Role of Spot Urine Protein-Creatinine Ratio in Monitoring Proteinuria during Pregnancy and Predicting Preeclampsia Outcomes

Dr. T. Vidhyalogini

Bhaarath Medical College and Hospital, Chennai-73, Tamil Nadu, India

Abstract: ***Proteinuria is a key diagnostic and prognostic marker in pregnancy-related hypertensive disorders, particularly preeclampsia. Traditionally, the 24-hour urine protein estimation has been considered the gold standard, but its time-consuming and error-prone nature limits clinical utility. The spot urine protein–creatinine ratio (UPCR) has emerged as a reliable, rapid, and patient-friendly alternative. This review explores the role of UPCR in monitoring proteinuria during pregnancy, its diagnostic accuracy in preeclampsia, its predictive value for maternal and fetal outcomes, and the implications for clinical practice in both high-resource and resource-limited settings. Current evidence supports UPCR as a practical tool, though standardization of cut-off values and integration into guidelines remain challenges [1–3].***

Keywords: Spot urine protein–creatinine ratio (UPCR), Proteinuria, Preeclampsia, Hypertensive disorders of pregnancy, Maternal outcomes, Fetal outcomes

1. Introduction

Hypertensive disorders of pregnancy, especially preeclampsia, are major contributors to maternal and perinatal morbidity and mortality worldwide. Preeclampsia affects approximately 2–8% of pregnancies globally, with higher incidence in low- and middle-income countries [4]. A hallmark of preeclampsia is proteinuria, reflecting endothelial dysfunction and renal involvement. Monitoring proteinuria is crucial not only for diagnosis but also for assessing severity, progression, and prognosis [5].

The 24-hour urine protein collection has traditionally been considered the gold standard for quantifying proteinuria. However, it is cumbersome, prone to collection errors, and often impractical in busy clinical settings [6]. In contrast, the spot urine protein–creatinine ratio (UPCR) offers a convenient, quicker, and more reproducible method [7,8].

Pathophysiological Background

Preeclampsia is characterized by systemic endothelial dysfunction, abnormal placentation, and imbalance in angiogenic factors. Renal manifestations include glomerular endotheliosis, leading to increased permeability of the glomerular basement membrane [9,10]. Proteinuria is the clinical manifestation of this renal involvement. Reliable quantification of proteinuria is therefore essential for early recognition and timely intervention.

Traditional Methods of Proteinuria Assessment

Dipstick Testing

Urine dipstick analysis is widely used for initial screening. While inexpensive and rapid, it suffers from significant variability due to urine concentration, hydration status, and observer interpretation. Its sensitivity and specificity for diagnosing significant proteinuria (>300 mg/day) are suboptimal [11].

24-Hour Urine Protein Estimation

The 24-hour urine protein test remains the reference standard. However, it is often inconvenient, requiring strict adherence to collection protocols, which patients may not always follow [6]. Incomplete collection can lead to underestimation of proteinuria. Moreover, waiting 24 hours for results delays clinical decision-making in urgent obstetric situations [12].

Spot Urine Protein–Creatinine Ratio: Concept and Methodology

UPCR involves measuring protein and creatinine concentrations in a single voided urine sample and expressing proteinuria as a ratio to creatinine excretion. Since creatinine excretion is relatively constant, the ratio provides a reliable estimate of total daily protein excretion [7,9].

Advantages of UPCR include:

- Rapid availability of results
- No need for timed urine collection
- Greater patient compliance
- Reduced laboratory errors
- Applicability in outpatient and emergency settings [5,8]

Diagnostic Accuracy of UPCR in Pregnancy

Several studies have demonstrated strong correlations between UPCR and 24-hour urine protein excretion. Correlation coefficients often exceed 0.8, suggesting that UPCR is a reliable surrogate marker [9,13].

- Cut-off values: A UPCR ≥0.3 (mg/mg) is commonly used as equivalent to ≥300 mg/day proteinuria [14]. Some studies suggest higher thresholds (e.g., 0.35 or 0.5) for improved specificity, while lower cut-offs may enhance sensitivity [15].
- Meta-analyses confirm that UPCR has high sensitivity (80–95%) and specificity (70–90%) in diagnosing significant proteinuria [8,16].

Thus, UPCR provides a practical balance between accuracy and feasibility, especially in time-sensitive obstetric care.

Role of UPCR in Monitoring Proteinuria During Pregnancy

Monitoring progression of proteinuria is vital in high-risk pregnancies. UPCR enables frequent and timely assessments without burdening patients [7].

- Serial measurements: Trends in UPCR correlate well with disease progression and can guide therapeutic interventions [5,17].
- Treatment monitoring: UPCR can help evaluate response to antihypertensive therapy and decisions regarding hospitalization or delivery [18].
- Resource-limited settings: In areas where 24-hour collection is impractical, UPCR offers a reliable alternative for ongoing monitoring [19].

Predictive Value of UPCR in Preeclampsia Outcomes

Preeclampsia can lead to serious maternal complications (eclampsia, HELLP syndrome, renal failure, stroke) and adverse fetal outcomes (intrauterine growth restriction, preterm birth, perinatal mortality) [20]. Proteinuria severity has traditionally been associated with worse outcomes, though recent guidelines caution against using proteinuria alone for prognosis [11,21].

Maternal Outcomes

- Higher UPCR levels are associated with increased risk of severe hypertension, need for intensive care, and development of complications such as HELLP syndrome [5,15].
- Women with persistently elevated UPCR are more likely to require early delivery and have prolonged hospital stays [16,22].
- Fetal Outcomes
- Elevated UPCR correlates with small-for-gestational-age infants, intrauterine growth restriction, and preterm delivery [14,19].
- UPCR >1.0 has been linked with adverse neonatal outcomes including low birth weight and NICU admissions [5,7].

Prognostic Value

While UPCR should not be used in isolation to predict outcomes, when combined with clinical parameters (blood pressure, biomarkers, Doppler studies), it strengthens risk stratification [23,24].

Comparison with Emerging Biomarkers

New biomarkers such as sFlt-1/PlGF ratio and angiogenic factors are being studied for predicting preeclampsia [14,23]. While these show promise in precision risk assessment, they are costly and less available in routine clinical practice. UPCR, on the other hand, is inexpensive, widely available, and easily interpretable, making it highly valuable, especially in low- and middle-income countries [19,25].

Limitations of UPCR

Despite its advantages, UPCR has certain limitations:

- Variability due to diurnal changes and recent physical activity
- Influence of urinary tract infections or hematuria
- Lack of universally accepted cut-off values across populations
- Not a direct predictor of disease severity independent of other clinical factors [6,11]

Hence, UPCR should complement, not replace, comprehensive maternal-fetal assessment.

Clinical Practice Implications

Guidelines from various obstetric societies now endorse UPCR as an acceptable alternative to 24-hour urine collection for diagnosing significant proteinuria [11,26]. In clinical practice:

UPCR can be used as the initial diagnostic test when preeclampsia is suspected [8]. Serial UPCR measurements provide a non-invasive monitoring tool during antenatal care [7,15]. UPCR can aid in timely decision-making regarding hospitalization, corticosteroid administration for fetal lung maturity, or early delivery [17,21]. In resource-limited regions, UPCR has the potential to significantly improve maternal and fetal outcomes by enabling wider access to proteinuria assessment [19,20].

2. Future Directions

1) Standardization: Establishing universally accepted cut-off values specific to pregnancy is crucial [12].
2) Integration with risk models: Combining UPCR with angiogenic markers, Doppler velocimetry, and clinical scoring systems may enhance predictive accuracy [23].
3) Long-term outcomes: Further research is needed on whether UPCR levels in pregnancy predict future maternal cardiovascular or renal risk [17,18].
4) Technological innovations: Development of point-of-care UPCR testing could revolutionize antenatal monitoring, especially in rural settings [25].

3. Conclusion

The spot urine protein–creatinine ratio is a valuable tool for monitoring proteinuria in pregnancy and predicting outcomes in preeclampsia. It offers rapid, reliable, and cost-effective assessment compared to the cumbersome 24-hour urine collection. While it cannot fully replace clinical judgment or emerging biomarkers, UPCR has earned its place in routine obstetric practice as a pragmatic and evidence-based approach. Standardization of cut-off values, integration into comprehensive risk assessment models, and continued research will further enhance its utility in safeguarding maternal and fetal health [1,5,7,19].

References

[1] Bartal MF, Melamed N, Yagel S. Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance. Am J Obstet Gynecol. 2022; 226(6): 699-711.
[2] Xiao J, Tang Y, Wang C. Diagnosis of proteinuria using a random urine protein-creatinine ratio. J Clin Lab Anal. 2022;36(9): e24613.
[3] Bertoni I, Cioni E, D'Ambrosio F, Paulesu E. Approach to investigation and management of proteinuria in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2024; 94: 102-115.

[4] American College of Obstetricians and Gynecologists. Preeclampsia work up. ACOG Clinical Resource. 2019. Available from: https://www.acog.org
[5] Chadha A, Malik R, Sethi M. Urinary protein-to-creatinine ratio: An indicator of adverse fetomaternal outcomes in preeclampsia. J Obstet Gynaecol India. 2022;72(5):660-666.
[6] Stefańska K, Zieliński M, Zamkowska D, et al. Comparisons of dipstick test, urine protein-to-creatinine ratio, and total protein measurement for the diagnosis of preeclampsia. Int J Environ Res Public Health. 2020;17(12):4195.
[7] Yang PY, Hsu SC, Huang LW, et al. Comparisons of urine protein-to-creatinine ratios and their associations with maternal and perinatal outcomes in hypertensive pregnancies. Int J Med Sci. 2022;19(3):1473-1482.
[8] Waugh J, Hooper R, Lamb E, et al. Spot protein-creatinine ratio and albumin-creatinine ratio in preeclampsia: diagnostic accuracy and cost-effectiveness. Health Technol Assess. 2017;21(1):1-90.
[9] Sánchez SE, Alarcón A, Sánchez E, et al. Utility of the spot urine protein/creatinine ratio to assess proteinuria in pregnant women with hypertension. Am J Obstet Gynecol. 2005;193(2):722-727.
[10] Wheeler TL, Blackhurst DW, Dellinger EH, Ramsey PS. Usage of spot urine protein-creatinine ratios in the evaluation of preeclampsia. Am J Obstet Gynecol. 2007;196(5): 465.e1-465.e4.
[11] Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised ISSHP statement. Pregnancy Hypertens. 2014;4(2):97-104.
[12] Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2014;36(5):416-441.
[13] Roberts JM, Hubel CA. The two-stage model of preeclampsia: variations on the theme. Placenta. 2009;30 Suppl A:S32-S37.
[14] Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and risk of preeclampsia. N Engl J Med. 2004;350(7):672-683.
[15] Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31(1):33-46.
[16] Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol. 2009;200(5):481-485.
[17] Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
[18] Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and risk of end-stage renal disease. N Engl J Med. 2008;359(8):800-809.
[19] Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2): e003497.
[20] Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-799